首页> 美国卫生研究院文献>Journal of Clinical Oncology >Multicenter Randomized Open-Label Phase III Trial of Decitabine Versus Patient Choice With Physician Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

【2h】

Multicenter Randomized Open-Label Phase III Trial of Decitabine Versus Patient Choice With Physician Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

机译：地卡他滨与患者选择的多中心随机开放标签III期试验在医生的建议下支持治疗或小剂量阿糖胞苷治疗新诊断为急性髓性白血病的老年患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThis multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics.

机译：目的这项多中心，随机，开放标签，III期试验比较了地西他滨与治疗选择（TC）在新诊断为急性髓细胞性白血病（AML）和低危或中危细胞遗传学的老年患者中的疗效和安全性。

著录项

期刊名称 Journal of Clinical Oncology
作者
Hagop M. Kantarjian; Xavier G. Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur;
展开▼
作者单位

展开▼
年(卷),期 -1(30),21
年度 -1
页码 2670–2677
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J] . KantarjianH.M., ThomasX.G., DmoszynskaA., Journal of Clinical Oncology . 2012,第21期

机译：地西他滨与患者选择的多中心，随机，开放标签III期试验，在医生的建议下，支持治疗或小剂量阿糖胞苷治疗新诊断为急性髓性白血病的老年患者
2. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics [J] . Ji?í Mayer, Christopher Arthur, Jacques Delaunay, BMC Cancer . 2014,第1期

机译：地西他滨与新诊断为急性髓样白血病且细胞遗传学风险中等或中等风险的老年患者的地西他滨与治疗选择支持治疗或阿糖胞苷的随机，多国，3期临床试验的多变量和亚组分析
3. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J] . Amadori Sergio, Suciu Stefan, Selleslag Dominik, Journal of Clinical Oncology . 2016,第9期

机译：Gemtuzumab Ozogamicin与较新的急性髓样白血病不适合强化化疗的老年患者的最佳支持治疗：III期EORTC-GIMEMA AML-19随机试验的结果
4. Analysis of Competing Endogenous RNA Network and Prediction of Prognosis in Acute Lymphoblastic Leukemia Patients of Phase II and III [C] . Jianzhi Deng, Xiaohui Cheng, Yuehan Zhou International Conference on Modelling, Simulation and Big Data Analysis . 2019

机译：竞争内源性RNA网络的分析及III期急性淋巴细胞白血病患者预后预测
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Multivariate and subgroup analyses of a randomized multinational phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics [O] . Jiří Mayer, Christopher Arthur, Jacques Delaunay, 2014

机译：对新诊断为急性髓样白血病且细胞遗传学风险中等或中等风险的老年患者进行的地西他滨与治疗选择支持治疗或阿糖胞苷的随机多国3期试验的多变量和亚组分析
7. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia [O] . Hagop M. Kantarjian, Xavier G. Thomas, Anna Dmoszynska, 2012

机译：多中心，随机，开放标签，阶段审判与患者选择，具有患者建议，用于治疗新诊断的新诊断急性髓性白血病的老年患者

Multicenter Randomized Open-Label Phase III Trial of Decitabine Versus Patient Choice With Physician Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

摘要

著录项

相似文献

相关主题

期刊订阅